Clinical Trial Update: A Trial of Setmelanotide in Acquired Hypothalamic Obesity [Phase 3]

View source ↗

Summary

Rhythm Pharmaceuticals provides an update on a Phase 3 trial of setmelanotide for hypothalamic obesity, with the study currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypothalamic Obesity

Drugs mentioned

• IMCIVREE (setmelanotide)

Snippet

Sponsor: Rhythm Pharmaceuticals, Inc. | Conditions: Hypothalamic Obesity | Phase 3 | Status: ACTIVE_NOT_RECRUITING